Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1318-1320

  Reddy, N ^a   Greer, J P ^a   Goodman, S ^a   Engelhardt, B ^a   Oluwole, O ^a   Jagasia, M H ^a   Savani, B N ^a  

^a Department of Medicine   (United States)

Author keywords

Follicular lymphoma; Relapse; SCT; Survival

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RITUXIMAB;

ADULT; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MALE; MORTALITY; NONRELAPSE MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; SALVAGE THERAPY;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867396809     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.10     Document Type: Article

References (15)

1. Khouri IF. Allogeneic stem cell transplantation in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 271-277.
2. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236-245.
3. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011; 17: 1051-1057.
4. Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011; 86: 768-775.
5. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
6. de Lavallade H, Mohty M, El-Cheikh J, Cassier PA, Faucher C, Fürst S et al. Reducedintensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006; 135: 408-410.
7. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
8. Shafey M, Lupichuk SM, Do T, Owen C, Stewart DA. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant 2011; 46: 962-969.
9. Freytes CO, Lazarus HM. Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? Bone Marrow Transplant 2009; 44: 559-569.
10. Reddy N, Savani BN. Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant 2011; 17: 1265-1272.
11. Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reducedintensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395-1403.
12. Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176-1182.
13. Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo- SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 2011; 46: 1503-1509.
14. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009; 43: 383-397.
15. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701-708.